JP2006525786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006525786A5 JP2006525786A5 JP2004563747A JP2004563747A JP2006525786A5 JP 2006525786 A5 JP2006525786 A5 JP 2006525786A5 JP 2004563747 A JP2004563747 A JP 2004563747A JP 2004563747 A JP2004563747 A JP 2004563747A JP 2006525786 A5 JP2006525786 A5 JP 2006525786A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- btl
- amino acids
- protein
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 44
- 102100025429 Butyrophilin-like protein 2 Human genes 0.000 claims 40
- 101000934738 Homo sapiens Butyrophilin-like protein 2 Proteins 0.000 claims 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 239000012634 fragment Substances 0.000 claims 10
- 230000002163 immunogen Effects 0.000 claims 9
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 230000006052 T cell proliferation Effects 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000016379 mucosal immune response Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000003313 weakening effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43618502P | 2002-12-23 | 2002-12-23 | |
| US52529803P | 2003-11-26 | 2003-11-26 | |
| PCT/US2003/040338 WO2004058986A2 (en) | 2002-12-23 | 2003-12-19 | Btl-ii nucleic acids, proteins, and antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006525786A JP2006525786A (ja) | 2006-11-16 |
| JP2006525786A5 true JP2006525786A5 (enExample) | 2007-01-25 |
| JP4671694B2 JP4671694B2 (ja) | 2011-04-20 |
Family
ID=32685440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563747A Expired - Fee Related JP4671694B2 (ja) | 2002-12-23 | 2003-12-19 | Ｂｔｌ−ｉｉ核酸、タンパク質および抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US7244822B2 (enExample) |
| EP (1) | EP1585760B1 (enExample) |
| JP (1) | JP4671694B2 (enExample) |
| AU (1) | AU2003299687B2 (enExample) |
| CA (1) | CA2509999A1 (enExample) |
| ES (1) | ES2391949T3 (enExample) |
| MX (1) | MXPA05006535A (enExample) |
| PL (2) | PL400309A1 (enExample) |
| WO (1) | WO2004058986A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2927242A1 (en) | 2010-04-09 | 2015-10-07 | Amgen, Inc | Btnl9 proteins, nucleic acids, and antibodies and uses thereof |
| CN104703999A (zh) | 2012-07-19 | 2015-06-10 | 安姆根有限公司 | 人btnl3蛋白、核酸和抗体及其用途 |
| JP5830048B2 (ja) * | 2013-03-15 | 2015-12-09 | 信越化学工業株式会社 | チタン含有レジスト下層膜形成用組成物及びパターン形成方法 |
| EP3661537A4 (en) * | 2017-08-03 | 2021-06-09 | The Cleveland Clinic Foundation | ENHANCED PEPTIDIC EXPRESSION AND DETECTION OF APO-H SPECIFIC SUBJECT ANTIBODIES |
| US20210032334A1 (en) * | 2018-02-28 | 2021-02-04 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents |
| EP4373513A1 (en) * | 2021-07-20 | 2024-05-29 | Regeneron Pharmaceuticals, Inc. | Butyrophilin-like 2 for treating inflammatory disorders |
| CN114437234A (zh) * | 2021-12-28 | 2022-05-06 | 四川省医学科学院·四川省人民医院 | Btnl2重组蛋白及其制备方法与在制备用于治疗炎症性肠病药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6641809B1 (en) * | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| WO2001053836A2 (en) | 2000-01-24 | 2001-07-26 | Millennium Pharmaceuticals, Inc. | Identification, assessment, prevention, and therapy of prostate cancer |
| DE10032529A1 (de) | 2000-06-30 | 2002-02-07 | Epigenomics Ag | Diagnose von bedeutenden genetischen Parametern innerhalb des Major Histocompatibility Complex (MHC) |
| EP1328624B1 (en) * | 2000-09-20 | 2011-11-09 | Amgen Inc. | B7-like molecules and uses thereof |
| NZ525336A (en) | 2000-10-20 | 2006-03-31 | Expression Diagnostics Inc | Leukocyte expression profiling |
| US20040166490A1 (en) | 2002-12-17 | 2004-08-26 | Morris David W. | Novel therapeutic targets in cancer |
| AU2003210309A1 (en) | 2002-02-20 | 2003-09-09 | Universiteit Gent | Method of modulating e-cadherin mediated cell adhesion |
-
2003
- 2003-12-19 JP JP2004563747A patent/JP4671694B2/ja not_active Expired - Fee Related
- 2003-12-19 EP EP03799969A patent/EP1585760B1/en not_active Expired - Lifetime
- 2003-12-19 AU AU2003299687A patent/AU2003299687B2/en not_active Ceased
- 2003-12-19 MX MXPA05006535A patent/MXPA05006535A/es active IP Right Grant
- 2003-12-19 US US10/742,682 patent/US7244822B2/en not_active Expired - Fee Related
- 2003-12-19 PL PL400309A patent/PL400309A1/pl not_active Application Discontinuation
- 2003-12-19 CA CA002509999A patent/CA2509999A1/en not_active Abandoned
- 2003-12-19 ES ES03799969T patent/ES2391949T3/es not_active Expired - Lifetime
- 2003-12-19 PL PL379564A patent/PL379564A1/pl not_active IP Right Cessation
- 2003-12-19 WO PCT/US2003/040338 patent/WO2004058986A2/en not_active Ceased
-
2007
- 2007-06-08 US US11/760,515 patent/US7709618B2/en not_active Expired - Fee Related
-
2010
- 2010-03-03 US US12/716,594 patent/US8173603B2/en not_active Expired - Fee Related
-
2012
- 2012-04-10 US US13/443,652 patent/US8674078B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7247226B2 (ja) | 水痘・帯状疱疹ウイルスの抗原バリアントおよびその使用 | |
| JP2006515749A5 (enExample) | ||
| JP2017122120A5 (enExample) | ||
| JP2013517783A5 (enExample) | ||
| JP2013541335A5 (enExample) | ||
| JP2010166921A5 (enExample) | ||
| JP2009540801A5 (enExample) | ||
| JP2012012402A5 (enExample) | ||
| JP6907229B2 (ja) | ヒト化抗ｃｌｅｖｅｒ−１抗体およびその使用 | |
| JP2002505843A5 (enExample) | ||
| Jiang et al. | Hantavirus Gc induces long-term immune protection via LAMP-targeting DNA vaccine strategy | |
| JP2005523681A5 (enExample) | ||
| JP7146926B2 (ja) | Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン | |
| JP2008545393A5 (enExample) | ||
| CN112996909B (zh) | 表达pd-1结合蛋白的溶瘤病毒及其应用 | |
| JP2006525786A5 (enExample) | ||
| JP2010517544A5 (enExample) | ||
| Namkoong et al. | Enhancement of antigen-specific CD8 T cell responses by co-delivery of Fc-fused CXCL11 | |
| JP6213969B2 (ja) | 免疫原性ポリペプチド表層発現ビフィズス菌 | |
| JP2010535504A5 (enExample) | ||
| CA3180251A1 (en) | Cytokine conjugates | |
| JP2010514698A5 (enExample) | ||
| CN106868025A (zh) | 用酵母制备三聚体埃博拉病毒糖蛋白突变体的方法 | |
| CA3192632A1 (en) | Herpesvirus polyepitope vaccines | |
| JP7554423B2 (ja) | デングウイルスワクチン |